Parkinson’s Disease | Access and Reimbursement | US | 2019

Systemic lupus erythematosus (SLE) is a complex autoimmune disease that can affect nearly any organ or system in the body. As a result, its course, manifestations, and treatment approach can be highly variable between patients. This lack of consistency has made clinical trial design, as well as understanding the potential market for therapies in SLE, a unique challenge. To date, GlaxoSmithKline’s Benlysta (2011) is the only drug to have launched for SLE in the G7 in more than 50 years; however, its modest efficacy is a deterrent to uptake. Of note, AstraZeneca’s Saphnelo (anifrolumab) was approved in 2021-2022 throughout the G7 for nonrenal SLE. Additionally, GlaxoSmithKline’s Benlysta and Aurinia’s Lupkynis (voclosporin) have been approved for adult patients with active lupus nephritis (LN). Several therapies (i.e., anifrolumab, dapirolizumab pegol, voclosporin, obinutuzumab, secukinumab, and BIIB059) in development for moderate to severe SLE without active renal disease and/or LN are expected to fulfill the high unmet need associated with this condition. The Disease Landscape & Forecast provides detailed analyses of current medical practice, key unmet needs, and new developments in the SLE space, along with an analysis of the opportunities and obstacles facing emerging agents.

Questions answered:

• How large is the treatable SLE population, and how will diagnosis / drug-treatment rates change over time?
• What is the current state of SLE treatment? What are the most important drugs for the treatment of patients without active renal disease and LN, and why? What are interviewed experts’ insights into current treatment options? What are the key unmet needs in SLE?
• What are KOLs’ perception of key emerging therapies, and where do they see these agents fitting into the treatment algorithm? What sales / uptake could these agents secure in SLE? What therapies of note are progressing in earlier phases?
• What are the drivers and constraints in the SLE market, and how will the market evolve over the forecast period?

Scope:

Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, and Japan.

Primary research: Approximately 26 country-specific interviews with rheumatologists and nephrologists.

Epidemiology: Diagnosed prevalence of SLE by country and subpopulations (nonrenal SLE and LN).

Population segments in market forecast: Total population, nonrenal SLE population, renal SLE (LN) population.

Emerging therapies: Phase II: 24 drugs; Phase III: 6 drugs.